What is Butterfly Network?
Butterfly Network, Inc. is a pioneering medical technology firm that develops, manufactures, and commercializes advanced ultrasound imaging solutions. Its core product suite, including the Butterfly iQ, iQ+, and iQ3, represents a paradigm shift in point-of-care diagnostics. By integrating whole-body imaging capabilities into a single handheld probe that interfaces seamlessly with smartphones, tablets, and hospital information systems, the company effectively bridges the gap between complex diagnostic hardware and accessible clinical workflows. Beyond human healthcare, the firm has successfully extended its reach into the veterinary sector with the Butterfly iQ+ Vet, demonstrating the versatility and broad market applicability of its semiconductor-based ultrasound technology.
How much funding has Butterfly Network raised?
Butterfly Network has raised a total of $352M across 3 funding rounds:
Private Equity
$100M
Unspecified
$250M
Debt
$2M
Private Equity (2014): $100M with participation from Aeris Capital AG
Unspecified (2018): $250M led by Fosun Pharma, Bill & Melinda Gates Foundation, and Fidelity
Debt (2020): $2M supported by PPP
Key Investors in Butterfly Network
Aeris Capital AG
Aeris Capital AG is a Zurich-based investment banking firm that provides strategic financial support to high-growth enterprises.
Fosun Pharma
A Shanghai-headquartered pharmaceutical giant focused on the research, development, and manufacturing of innovative healthcare products.
Fidelity
A global financial services leader providing comprehensive investment, wealth management, and advisory solutions to institutional and individual clients.
What's next for Butterfly Network?
With the recent capital injection, Butterfly Network is expected to prioritize the scaling of its software-as-a-service (SaaS) ecosystem, which enhances the utility of its hardware through AI-driven image guidance and cloud-based data management. The company's roadmap likely includes deepening its integration with enterprise hospital systems and expanding its global distribution network to reach underserved clinical settings. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward optimizing operational efficiency and driving widespread adoption of its handheld devices as the standard of care for bedside diagnostics. Investors will be closely monitoring the company's ability to maintain its competitive edge in the rapidly evolving digital health landscape while navigating the regulatory complexities inherent in medical device manufacturing.
See full Butterfly Network company page
